Alcon: Macular Degeneration trials

The registry lists 20 Macular Degeneration studies with Alcon as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 5Phase 2 8Phase 3 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular DegenerationCompletedNCT02507388Phase 2Results posted
• Efficacy and Safety of RTH258 Versus Aflibercept - Study 2CompletedNCT02434328Phase 3Results posted
• Efficacy and Safety of RTH258 Versus Aflibercept - Study 1CompletedNCT02307682Phase 3Results posted
• First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular DegenerationCompletedNCT02076919Phase 1Results posted
• ESBA1008 Microvolume StudyCompletedNCT01849692Phase 2Results posted
• Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular DegenerationCompletedNCT01835015Phase 1Results posted
• Efficacy and Safety Study of ESBA1008 Versus EYLEA®CompletedNCT01796964Phase 2Results posted
• A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)TerminatedNCT01603043Phase 2Results posted
• ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) PatientsCompletedNCT01304693Phase 1/2Results posted
• Evaluation of AL-78898A in Exudative Age-Related Macular DegenerationCompletedNCT01157065Phase 2Results posted
• Geographic Atrophy Treatment EvaluationTerminatedNCT00890097Phase 3Results posted
• A Study Assessing AR-13503 Implant in Subjects With nAMD or DMECompletedNCT03835884Phase 1
• Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular DegenerationTerminatedNCT02398500Phase 1/2
• WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment ExaminationCompletedNCT00992563Phase 2
• The Natural History of Geographic Atrophy Progression (GAP) StudyTerminatedNCT00599846
• Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)CompletedNCT00299507Phase 3
• Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMDTerminatedNCT00065728Phase 3
• An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMDCompletedNCT00058994Phase 3
• Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)CompletedNCT00051129Phase 3
• Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMDCompletedNCT00041483Phase 3